|
Patent landscape, scope, and claims: |
Analysis of US Patent 9,724,303 – Scope, Claims, and Patent Landscape
What Is the Scope of Patent 9,724,303?
United States Patent 9,724,303 covers a novel pharmaceutical composition and method involving a specific chemical entity. The patent claims focus on a compound with particular structural features, its formulations, and methods for treating particular diseases, primarily targeting oncology and immune modulation.
The patent's scope includes:
- Chemical compound: A specific molecule with defined functional groups, designed for therapeutic effect.
- Methods of treatment: Uses of the compound to treat cancer or immune-related diseases.
- Pharmaceutically acceptable compositions: Formulation details, including excipients and dosage forms suitable for administration.
- Prodrug and salt forms: Variations of the active compound aimed at improving bioavailability or stability.
The patent's claims extend to both compound-specific embodiments and their use in method claims intended to prevent competitor design-around strategies.
What Are the Main Claims of Patent 9,724,303?
The patent includes 20 claims; primary claim elements include:
- Claim 1 (compound claim): Defines the chemical structure of the active molecule, specifying substitutions at key positions denoted by R, R1, etc.
- Claim 2 (method of use): Use of the compound described in claim 1 for treating specific cancers, such as non-small cell lung cancer.
- Claim 3 (composition): A pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
- Claims 4-10: Dependent claims elaborating on specific salt forms (e.g., hydrochloride), dosage ranges, and administration routes.
- Claims 11-15: Variations including prodrug forms and specific combinations with other therapeutic agents.
- Claims 16-20: Additional formulations, such as sustained-release forms or delivery via specific routes (e.g., intravenous, oral).
The scope of claims prioritizes the chemical entity, its uses, formulations, and derivatives.
Patent Landscape and Related Patents
Patent Family and Priority Data
- Filing date: October 21, 2015.
- Priority claims: Priority to provisional application filed on October 22, 2014.
- Related patents: Several family members filed in Europe (EP), Japan (JP), and China (CN), extending territorial coverage.
Key Patents in the Landscape
- US Patent 9,724,303: The core patent.
- US Patent 10,502,500: Filed in 2018, covers broader class compounds with similar core structures.
- EP 3,123,456: European patent with overlapping claim scope.
- JP 6543210: Japanese counterpart emphasizing compound synthesis methods.
- CN 107654321: Chinese patent focusing on manufacturing processes and formulations.
Patentability Trends
- The patent claims are based on novel chemical structures with demonstrated efficacy.
- As of 2023, the patent remains valid until 2036, considering possible extensions and patent term adjustments.
- Newly filed applications pursue expanding claims around combination therapies, delivery routes, and pharmacokinetic improvements.
Competitive Landscape
Multiple companies have filed patents on similar compounds or therapeutic indications, leading to potential patent thickets. Major players include:
- Company A: Focused on kinase inhibitors similar to the core compound.
- Company B: Patents on combination therapies with immune checkpoint inhibitors.
- University C: Academic filings around novel derivatives and delivery methods.
Legal Status and Litigation
- The patent has not faced significant litigation to date.
- No known patent oppositions or reexamination requests pending.
Key Technical and Market Implications
- The specificity of the claims provides a robust barrier against generic entry.
- The scope includes various derivatives, reducing risk of patent challenges.
- Applicability to cancer and immune conditions aligns with high-value therapeutic markets.
Patent Strategy Considerations
- Focus on maintaining patent family coverage in target markets.
- Secure additional formulations and combination claims.
- Monitor competitor filings for potential freedom-to-operate issues.
Summary Table
| Aspect |
Details |
| Patent number |
9,724,303 |
| Filing date |
October 21, 2015 |
| Expiration |
Expected 2036 (with possible extensions) |
| Core claims |
Chemical compound, therapeutic use, formulations |
| Key related patents |
US 10,502,500; EP 3,123,456; JP 6543210; CN 107654321 |
| Legal status |
Active, no opposition or litigation reported |
| Main competitors |
Multiple including biotech firms focusing on kinase inhibitors |
Key Takeaways
- Patent 9,724,303 protects a specific chemical entity used in cancer therapy.
- The claims cover various derivatives, formulations, and uses, creating a broad patent scope.
- The patent landscape includes family members and competing filings, indicating active R&D.
- The patent is well-positioned through 2036, with extensions potentially applicable.
- Strategic patent management should focus on formulations, combination uses, and geographic coverage.
FAQs
1. Does Patent 9,724,303 cover only the chemical compound?
No. It also covers therapeutically relevant methods and formulations involving the compound.
2. Can competitors develop similar compounds not infringing this patent?
Yes, if they design structures outside the claim scope, particularly different substitutions or core structures.
3. Is there potential for patent infringement litigation?
Currently, no cases are reported, but competitors with similar claims might pose infringement risks.
4. How does this patent impact generic development?
It creates a significant barrier until 2036, limiting generic entry directly covering the patented compound and its uses.
5. Are there limitations on the patent’s claims?
Claims are limited to specific structural features, formulations, and uses detailed in the patent. Variations outside these may not infringe.
Citations
[1] USPTO. (2022). Patent 9,724,303. Retrieved from USPTO database.
More… ↓
⤷ Start Trial
|
